Eszter Csomor

Anifrolumab Treatment Leads to Rapid Reduction in Urinary Biomarkers of Intrarenal Inflammation in Lupus Nephritis: Results From the Phase 2 Randomized Trial

Andrea Fava, Michelle Petri, Patrick G. Gavin, Eszter Csomor et autres

OBJECTIVE: Lupus nephritis (LN) is one of the most severe manifestations of systemic lupus erythematosus (SLE) and is partially driven by type I interferon signaling. Anifrolumab, an approved treatment for patients with SLE, has been investigated in a phase 2 trial in …

us, fi, it (code pays fourni par la source)

Metabolomic profiling of patients with lupus nephritis reveals unique metabolites that are modulated through type I interferon inhibition by anifrolumab treatment in a phase 2 trial

Patrick G. Gavin, Erik L. Allman, David Jayne, Eduardo Mysler et autres

OBJECTIVE: Patients with systemic lupus erythematosus (SLE) commonly develop lupus nephritis (LN), the most frequent severe organ manifestation of this systemic autoimmune disease. Using serum and urine samples from a phase 2 trial in LN, we investigated that how the LN metabolome …

fi, jp, gb, fr, kr, se (code pays fourni par la source)

ABS0252 PREVALENCE OF IFN HIGH RHEUMATOID ARTHRITIS IN EARLY AND ESTABLISHED RA PATIENTS

Eszter Csomor, Lygia Stewart, Fraser Morton, Carolyn Paterson et autres

Background: A pathogenic role for type I interferons (IFN) has been hypothesized across multiple autoimmune indications, including rheumatoid arthritis (RA). Evidence in the literature shows that an elevated type I IFN gene signature (IFNGS) is present in the peripheral blood and synovial …

gb, us, se (code pays fourni par la source)

Epithelial Interleukin‐1 Receptor‐Like‐1 Activation Is Contingent on Interleukin‐33 Isoforms and Asthma‐Related Receptor Variation

Michael A. Portelli, Maria E. Ketelaar, Stewart Bates, Eszter Csomor et autres

ABSTRACT Introduction The interleukin‐33/interleukin‐1 receptor‐like‐1 (IL‐33/IL1RL1) signalling pathway is implicated in asthma pathogenesis, with IL1RL1 nonsynonymous genetic polymorphisms associated with disease risk. We aimed to determine these variants' effect on IL1RL1 signalling induced by different IL33 isoforms thought to be elevated in …

gb, nl (code pays fourni par la source)

A randomised, parallel-group, double-blind, placebo-controlled phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, In SYstemic sclerosis: DAISY study design and rationale

Dinesh Khanna, Christopher P. Denton, Shervin Assassi, Masataka Kuwana et autres

OBJECTIVES: The type I interferon pathway is a promising target for treatment of patients with systemic sclerosis (SSc). Here, we describe the design of a multinational, randomised phase 3 study to Determine the effectiveness of the type I interferon receptor antibody, Anifrolumab, …

us, gb, jp, fr, ch, it (code pays fourni par la source)

POS0407 TYPE I INTERFERON PATHWAY IS UPREGULATED IN GLOMERULAR AND TUBULOINTERSTITIAL KIDNEY COMPARTMENTS OF PATIENTS WITH LUPUS NEPHRITIS AND OTHER RENAL DISEASES

N. Ferrari, Eduardo Mysler, James A. Tumlin, Brad H. Rovin et autres

gb, us, de, se (code pays fourni par la source)

POS0409 IMPROVEMENTS IN CD163, A URINARY BIOMARKER OF RENAL INFLAMMATION, WITH ANIFROLUMAB: RESULTS FROM A PHASE 2 TRIAL IN LUPUS NEPHRITIS

N. Ferrari, Antonella Fava, M. Pétri, Patrick Gavin et autres

gb, us, se (code pays fourni par la source)

Type I interferon blockade with anifrolumab in patients with systemic lupus erythematosus modulates key immunopathological pathways in a gene expression and proteomic analysis of two phase 3 trials

Tina Baker, Hoda Sharifian, Paul J. Newcombe, Patrick G. Gavin et autres

INTRODUCTION: Anifrolumab is a type I interferon (IFN) receptor 1 (IFNAR1) blocking antibody approved for treating patients with systemic lupus erythematosus (SLE). Here, we investigated the immunomodulatory mechanisms of anifrolumab using longitudinal transcriptomic and proteomic analyses of the 52-week, randomised, phase 3 …

gb, se, us, au, sg, fi (code pays fourni par la source)

Integrated analysis of dermal blister fluid proteomics and genome-wide skin gene expression in systemic sclerosis: an observational study

Kristina E N Clark, Eszter Csomor, Corrado Campochiaro, N. W. Galwey et autres

Background: Skin fibrosis is a hallmark feature of systemic sclerosis. Skin biopsy transcriptomics and blister fluid proteomics give insight into the local environment of the skin. We have integrated these modalities with the aim of developing a surrogate for the modified Rodnan …

gb, us, nl (code pays fourni par la source)

Biological and clinical insights from a randomized phase 2 study of an anti-oncostatin M monoclonal antibody in systemic sclerosis

Christopher P. Denton, Francesco Del Galdo, Dinesh Khanna, Madelon C Vonk et autres

OBJECTIVES: The cytokine oncostatin M (OSM) is implicated in the pathology of SSc. Inhibiting OSM signalling using GSK2330811 (an anti-OSM monoclonal antibody) in patients with SSc has the potential to slow or stop the disease process. METHODS: This multicentre, randomized, double-blind, placebo-controlled …

gb, us, nl, ca, it (code pays fourni par la source)

P229 Integrated analysis of dermal blister fluid proteomics and skin biopsy transcriptomics gives new insight into pathogenesis of systemic sclerosis

Kristina E N Clark, Eszter Csomor, Corrado Campochiaro, Yee Voan Teo et autres

Abstract Background/Aims Suction blister fluid (BF) provides a unique opportunity to analyse the dermal microenvironment of SSc. We utilised an integrated approach to analyse proteomic data from dermal interstitial fluid and genome-wide transcriptomic data from skin biopsies from early dcSSc and healthy …

gb, in (code pays fourni par la source)

Molecular basis for clinical diversity between autoantibody subsets in diffuse cutaneous systemic sclerosis

Kristina E N Clark, Corrado Campochiaro, Eszter Csomor, Adam Taylor et autres

gb (code pays fourni par la source)